bluuebunny/crossref_metadata_2025_split huggingface dataset:
Preexisting pulmonary hypertension impact on in-hospital outcomes of cardiac implantable electrical device implantation
Authors: Margolis G , Hafner O S , Kazatsker M , Roguin A , Leshem E 
Published: October 2024

Abstract

Background
Preexisting pulmonary hypertension (PH) is associated with unfavorable in-hospital outcomes in cardiac as well as non-cardiac surgeries and procedures. However, its impact on cardiac implantable electronic device (CIED) implantations is not established.
We investigated the extent of preexisting PH among patients undergoing CIED implantations and evaluated its effect on in-hospital outcomes.

Methods
Using the National Inpatient Sample (NIS) database, we identified patients who were hospitalized in the US between 2016-2019 and underwent CIED implantation with a preexisting diagnosis of PH. Patients with any CIED in-situ were excluded. Sociodemographic, clinical data, in-hospital procedures and outcomes as well as in-hospital mortality were collected. Multivariable logistic regression models were used to identify predictors of in-hospital complications.

Results
An estimated total of 718,980 patients underwent CIED implantation during the study period. Of them, 74,150 patients (10.3%) had preexisting PH diagnosis.
Compared with non-PH patients, PH patients were older, had higher Charlson Comorbidity Index, and more often implanted with implantable cardioverter defibrillators and cardiac resynchronization therapy devices.
Higher rate of total complications was observed in PH patients (14.5% versus 9.9%; P&lt;0.001) driven mainly by respiratory complications as well as in-hospital mortality (2.3% versus 1.2%; P&lt;0.001). Multivariable analyses confirmed PH as an independent predictor for respiratory complications, total complications and in-hospital mortality.

Conclusion
Preexisting PH in patients undergoing CIED implantation was associated with increased risk for respiratory complications as well as in-hospital mortality in a US nationwide, all-comer registry.
Integrated plasma proteomics and myocardial tissue transcriptomics reveal elevated fibrosis markers in arrhythmogenic cardiomyopathy patients
Authors: Akdis D A , Wilzeck V , Tan G , Costa S , Matter C , Brunckhorst C , Winnik S H , Akdis C A , Saguner A M , Duru F 
Published: October 2024

Abstract

Background
Arrhythmogenic cardiomyopathy (ACM) is characterized by myocardial fibrofatty replacement and ventricular arrhythmias, with potential progression to heart failure. This study aims to identify ACM-specific biomarkers for improved prognosis and possible treatment strategies.

Methods
RNA sequencing and transcriptome analyses were performed in cardiomyocytes of 10 ACM patients, 10 dilated cardiomyopathy patients and 10 healthy controls. Analyses were performed using liquid chromatography and mass spectrometry. Additionally, plasma protein expression was assessed in 38 ACM patients and 24 healthy controls using the Proximity Extension Assay (Olink®). A standardized bicycle exercise test was performed in 11 ACM patients and controls and blood was obtained before and after exercise.

Results
Myocardial tissue transcriptomics identified several upregulated molecules associated with extracellular matrix formation and immune response in ACM. Plasma protein sequencing revealed upregulation of proteins involved in metabolic pathways, inflammation, and fibrosis. Integration of these analyses identified key soluble profibrotic markers such as Fibulin-3, Endostatin and C-X-C motif chemokine 10 (CXCL10) in plasma of ACM patients. After exercise, Fibulin-3 levels increased in ACM patients compared to controls. These findings were further validated using enzyme-linked immunosorbent assay (ELISA).

Conclusion
This comprehensive analysis revealed distinct proteomic and transcriptomic signatures in ACM patients' plasma and cardiomyocytes. The integrative analysis identified several upregulated profibrotic markers in ACM. Our Findings may advance diagnostic and prognostic strategies and offer potential therapeutic targets.
Performance of the 2020 ACC/AHA and 2023 ESC risk stratification scales for primary prevention of sudden cardiac death in a Latin American population with hypertrophic cardiomyopathy
Authors: Casillas Munoz J P , Contreras Castillo P L , Nava Townsend S , Sanchez Contreras C A , Bazbaz Mizrahi A , Manzanarez Barrera J A , Marquez Murillo M F 
Published: October 2024

Abstract

Background
Identifying patients with hypertrophic cardiomyopathy (HCM) who are at high risk of sudden cardiac death (SCD) is essential for managing this condition. The American Heart Association/American College of Cardiology (AHA/ACC) and European Society of Cardiology (ESC) guidelines help assess and stratify the risk of determining which patients would benefit from primary prevention with an implantable cardioverter-defibrillator (ICD).

Objective
The study aims to evaluate the performance of the 2020 AHA/ACC and 2023 ESC risk stratification scales (AHA/ACC-rss; ESC-rss) for the primary prevention of SCD in Latin-American patients diagnosed with HCM.

Methods
A retrospective cohort of HCM from a single-center was analyzed. The inclusion criteria were individuals aged 16 years or older, without a history of SCD, and who had not undergone any treatment such as myomectomy or septal ablation with alcohol (Figure 1). The primary outcome was the identification of SCD or an equivalent event (successful resuscitation after cardiac arrest or appropriate therapy from the ICD).

Results
One hundred twenty patients were included (mean age 46.2 years old) and the mean follow-up duration was 61.1 months. From the total sample, 10 patients (8.3%) experienced an equivalent SCD event; 7 patients (5.8%) were ICD-protected and 3 (2.5%) required external defibrillation. The ESC-rss showed a greater area under the ROC curve (AUC, 0.79; 95% CI 0.62-0.94 vs AUC, 0.63; 95% CI 0.49-0.78) and specificity (85%; 95% CI 63-92 vs 51%; 95% CI 37.3-64.5). Sensitivity was similar between both scales (AHA/ACC-rss: 77%; 95% CI 50-100 vs ESC-rss: 73%; 95% CI 43-100). Remarkably, 2.5% of the patients who experienced an equivalent of SCD were incorrectly identified as low-risk individuals by either the AHA/ACC-rss, ESC-rss, or both (Table 1).

Conclusion
The SCD risk stratification recommended by the ESC-rss demonstrated a more effective identification of Latin American patients with HCM for ICD placement because the area under the curve was more significant than those of the AHA/ACC-rss. This single-center study highlights the need for a multicenter prospective study in Latin America.
Machine-learning models to predict the risk of recurrent VT following catheter ablation in patients with structural heart disease
Authors: Futela P , Behera G , Woelber T , Prasitlumkum N , Amin H , Arunachalam Karikalan S , Heybati K , Pradeep A , Kapa S , Deshmukh A J , Kowlgi G N 
Published: October 2024

Abstract

Background
Ventricular tachycardia (VT) is a life-threatening arrhythmia that can complicate structural heart disease. While catheter ablation is effective in treating this condition, the recurrence of VT after the procedure continues to be a concern. Consequently, there is a need for a reliable system to evaluate the likelihood of arrhythmia recurrence following an ablation.

Objective
To predict recurrence or repeat ablation after a VT catheter ablation procedure using machine learning (ML) models.

Methods
We conducted a single-center, retrospective study of all patients undergoing catheter ablation for scar-related VT between 2012 and 2022. Data collected included demographics, comorbidities, medications, relevant laboratory abnormalities, electrocardiograms, echocardiograms, detailed procedural characteristics, and outcomes. Python version 3.8.5 for exploratory data analysis (EDA) and visualization. Using six different ML models from the training set (90:10 split), we used 34 variables to predict the primary outcome, including VT recurrence or repeat catheter ablation. The accuracy of these models was compared using ROC curves based on their performance on the test set.

Results
Out of 508 VT ablation procedures, 261 experienced a recurrence. Support Vector Classifier (SVM) performed the best, having an AUC of 0.73, followed by logistic regression at 0.69 (Figure A). SVM yielded sensitivity, specificity, positive and negative predictive values of 0.73, 0.73, 0.79, and 0.67, respectively. The F1 score was 0.70. Among the factors with the highest feature importance in the model, the most influential variable was the proceduralist’s experience level, followed by QRS width at baseline, LVEF, and patient’s age (Figure B).

Conclusion
Our model can predict recurrent VT after ablation with reasonable accuracy, outperforming the existing clinical risk scores significantly. Larger training sample sizes will help achieve more robust ML models and improve predictive accuracy further.Figure A: ROC curve depicting the AUROCB. Feature importance graph
Outcomes of ventricular tachycardia ablation with intracardiac echocardiography-a retrospective cohort study of the national inpatient sample
Authors: Raj K , Singh Dhaliwal J , T Han F , S Hoffmayer K , Ho G , Raissi F , K Feld G , E Krummen D , C Hsu J 
Published: October 2024

Abstract

Background
Intracardiac echocardiography (ICE) is being increasingly used in VT ablation. Sparse literature indicates that ICE reduces repeat VT ablation and VT-related admissions (1).

Objective
To determine if ICE reduced procedural complications, mortality, length of stay, and hospitalization costs in VT ablation.

Methods
Utilizing the National Inpatient Sample (NIS) of the years 2016 to 2020, we compared the differences between patients who had VT ablation with and without ICE. We used multivariable logistic and linear regression models as appropriate to determine if ICE was associated with improved outcomes as defined above.

Results
We included 15,480 hospitalizations (95% CI 14,513-16,446) with VT ablations. ICE was used in 1815 (11.7%) of the patients. The mortality rate was 2.2%(95% CI 1.1-4.3) in the ICE group and 3.2% (95% CI 2.6-3.9) in the non-ICE group, and composite complications rate was 18.4% (95% CI 14.7-22.7) in the ICE group and 19.2% (17.7-20.8) in the non-ICE group. On univariate and multivariate analysis, ICE was not associated with a decrease in mortality, composite complications, or hospitalization charges but with a reduction in length of stay (Tables 1 and 2). ICE was associated with sepsis on univariate analysis but not on multivariate analysis (aOR 0.51, 95% CI 0.26-1.00, P=0.051)

Conclusion
Our study demonstrates that ICE was not associated with a reduction in mortality or complications in VT ablation but was associated with a slightly shorter length of stay. Although our observational study did not demonstrate a major benefit with ICE, given the multiple advantages of ICE in VT ablations, such as real-time recognition of myocardial substrate, identification of anatomical structures to guide ablation, and prompt recognition of intra-procedural complications, we recommend randomized controlled studies to evaluate the efficacy of ICE(2). Our study is limited by its retrospective nature and reliance on ICD codes for data extraction.
Nationwide trends in utilization and safety of ventricular arrythmia ablation in patients with hypertrophic cardiomyopathy
Authors: John K , Chee J , Chalhoub F , Infeld M , Homoud M , Ruskin J , Heist K , Udelson J , Madias C , Rozen G 
Published: October 2024

Abstract

Background
Catheter ablation for ventricular arrhythmias, including ventricular tachycardia (VT) and premature ventricular complexes (PVC) is increasingly utilized across the nation, while data on its safety in Hypertrophic Cardiomyopathy (HCM) patients is sparse.

Purpose
To analyze the nationwide trends in utilization and complications of inpatient ventricular arrhythmia ablations in patients with HCM.

Methods
This study is a retrospective analysis of hospitalizations, in HCM patients 18 years of age and older, who underwent an inpatient VA ablation in the U.S., between 2016 and 2020. We drew data from the National Inpatient Sample (NIS) database. Patients without HCM undergoing the CA for VA were used as controls. Baseline sociodemographic and clinical data, procedural complications, mortality and length of stay were analyzed. Multivariable analysis was performed to identify independent predictors of procedural complications.

Results
Among a weighted total of 2880 patients hospitalized between 2016 and 2020, who underwent VA ablations, the median age was 67 years (IQR 56-74), 60% were male, and 73% were white. The HCM group had similar age distribution but more women (64.5% vs 33.6%, p&lt;0.001) and more African Americans (13.2% vs. 7.3%, p=0.03). The non-HCM cohort had significantly higher rates of prior myocardial infarction (22% vs 12.4%, p=0.026), ischemic cardiomyopathy (30.1% vs 0.8%, p&lt;0.001), heart failure (70.5% vs 39.7%, p&lt;0.001), and peripheral vascular disease (PVD, 42.9% vs 18.2%, p&lt;0.001). This was reflected in higher Deyo Comorbidity Index in the non-HCM cohort (score of ≥ 2 in 66.6% vs 43%, p&lt;0.001). Overall, the real-world peri-procedural complication rate in the entire cohort was 15.3%, including 6.4% hemorrhagic, 4.5% pericardial, and 2.3% vascular complications. There was a trend for lower complication rate in the HCM group (9.9% vs. 16.7%, p = 0.08). The in-hospital mortality didn’t defer (1.7% vs. 4.2%, p=0.28) and the length of stay was shorter in the HCM group (3.5 vs. 6.4 days, p &lt; 0.001). Multivariable logistic regression analysis showed obesity (OR 2.06; 95%CI: 1.59 - 2.67; p&lt;0.001) and PVD (OR 2.19; 95%CI: 1.34-3.53; p=0.001) to be independent predictors of complications while HCM was not (OR 0.76, 95% CI 0.51-1.14, p = 0.195).

Conclusion
Real-world data from a nationwide inpatient database shows comparable safety for VA ablation in HCM patients with similar mortality and lower length of stay, compared to non-HCM patients.
Safety profile, electrical performances and clinical outcomes of a novel leadless pacemaker; first results from real-world clinical practice in Saudi Arabia
Authors: Sweidan R S , Bokhari F B , Chami A C , Grammatico A G , Al-Samadi F A 
Published: October 2024

Abstract

Introduction
Leadless pacemakers (LP) are emerging as an effective and safe alternative to transvenous pacemakers to reduce lead-related and pocket-related complications and to improve patient experience. A new LP system, the Aveir VR, has been approved in 2022 for US and other countries, and in 2023 for Europe, and features innovative characteristics such as the active fixation helix mechanism and the possibility to measure sensing/pacing parameters before LP deployment.

Purpose
Evaluate safety, electrical performances and clinical outcomes associated with the first Aveir VR LP implants in 2 Hospitals in Saudi Arabia.

Methods
We performed a prospective evaluation of all-comer patients who received Aveir VR LP. Decision for LP implant was based on conditions such as cardiac pacing indication, lack of upper extremity venous access, risk of device infection, and life expectancy, and using shared decision-making. Clinical and electrical data were collected at implant and at 1st and 6th month visits.

Results
A total of 54 patients (25 female, mean age 69 years) were included between December 2022 and October 2023. Pacemaker implant indication was AV block in 25 (46%) patients, sinus node disease in 19 (35%) patients, atrial fibrillation and slow ventricular response in 9 (17%) patients and left bundle branch block in 1 (2%) patient. Implant was successful in all attempted cases. Final device position was lower septum in 51/54 (94.4%) patients and mid-septum in 3/54 (5.6%) patients. Mean procedure time was 48±22 minutes and showed a decreasing trend as a function of operator experience with a mean of 55, 50 and 36 minutes in the first, second and third group of consecutive implants, respectively. Mean fluoroscopic time was 11±8 minutes and showed a decreasing trend as a function of operator experience with a mean of 13, 13 and 6 minutes in the first, second and third group of consecutive implants, respectively. Final device position was achieved at first attempt in 42/54 (77.8%) cases and at first or second attempt in 51/54 (94.4%) cases. At implant mean R wave sensing was 7.6±3.7 mV, mean impedance was 724±335 Ohm, mean threshold was 1.0±0.6 V at 0.4 ms. During implant there was one patient with pericardial effusion treated with pericardiocentesis. In a mean follow-up of 73 days there were no procedure-related or device-related complications, electrical parameters showed acceptable values, and all implanted devices performed as expected. Median longevity, estimated at last follow-up visit, was 19 years (interquartile range: 12-20 years).

Conclusion
First real-world cases of use of a novel leadless pacemaker in Saudi Arabia show optimal feasibility and good safety profile and electrical performances. Procedure and fluoroscopic times were acceptable and decreased as a function of operator experience. Longevity estimations predict very long service life-times.
Long-term follow-up of single-chamber atrial pacing - system upgrade and wenckebach block point behavior: potential implications for leadless AAI pacing?
Authors: Arnet R , Badertscher P , Isenegger C , Minder J , Jordan F , Salis M , Spreen D , Knecht S , Krisai P , Osswald S , Sticherling C , Schaer B , Kuehne M 
Published: October 2024

Abstract

Introduction
Until recently leadless pacemakers (PM) did not support atrial pacing. A novel dual chamber leadless PM system now provides treatment option for a wide range of indications. Single-chamber atrial stimulation (AAI) for the treatment of symptomatic sick sinus syndrome (SSS) is scarcely used due to concerns about the potential development of atrioventricular block (AVB) and development of paroxysmal atrial fibrillation (AF). Long-term follow-up data of AAI-PM is however scarce. Little is known about the role of serial Wenckebach block point (WBP) measurements in AAI-PM patients for risk stratification.

Purpose
To assess the incidence of dual chamber upgrade of patients treated with AAI-PM for SSS during long-term follow-up and to investigate the role of serial WBP measurements for risk stratification.

Methods
Prospectively enrolled patients undergoing implantation of an AAI-PM between October 2002 and December 2023. WBP was measured at implantation and serially during follow up.

Results
We included a total of 178 patients, of which 58% were female and the median age at implantation was 78 [IQR 71 – 83] years. The median follow-up duration was 6.5 [IQR 2.0 – 9.7] years. 24 patients (13.5%) received a system upgrade to DDD including 3 patients (1.7%) with a mode change to ventricular pacing only (VVI). Adjusted for years of follow-up the upgrade rate was 2.1% per year. Median time to system upgrade was 5.2 [IQR 1.6 – 8.7] years. Reasons for system upgrade were high-degree AVB (38%), low WBP (17%), atrial arrhythmias (33%), unclear syncope (8%) and infection (4%). Median WBP at implantation was 130 [120 – 140] bpm, showing a significant decline over time in the upgrade-group with 105 [95 – 130] bpm compared to the rest of the cohort with 130 [120-130] bpm (p = 0.009). A decline in WBP &gt;20 bpm was found in 17.9% patients and a decline of 10-20 bpm in 33.7% of patients. New-onset atrial arrythmias were found in 36 patients (20%), 29% in the upgrade group and 19% in the rest of the cohort (p = 0.3). Neither age at implantation, sex, WBP at implantation, nor atrial arrhythmia prior to implantation were predictive for the need of a future system upgrade.

Conclusion
In this cohort of patients undergoing AAI-PM implantation for SSS, a system upgrade was required in 2% per year. The WBP remained stable in 48% of patients. Therefore, AAI-PM due to SSS emerges as a judicious and secure therapeutic modality, warranting increased consideration in the light of new treatment options for leadless pacing.
Pacing sensation with a second generation intercostal extravascular ICD lead
Authors: Burke M C , Doshi S , Ebner A , Husby M , Marcovecchio A , Sanghera R , Scheck D , O'connor M , Chen S , Knops R E 
Published: October 2024

Abstract

Background/Introduction
An investigational intercostal extravascular ICD lead (EV-ICD Lead) has been developed to provide antitachycardia pacing and shock treatment of ventricular tachyarrhythmias when connected to a commercially available ICD pulse generator. Unlike other available extravascular ICD systems that achieve pacing with ring electrodes which transmit undirected current to cardiac and non-cardiac tissue alike, the intercostal EV-ICD Lead uses button-shaped electrodes backed by an insulative paddle to direct current toward excitable myocytes while minimizing undesired excitation of the adjacent tissues.

Purpose
The purpose of this analysis was to evaluate pacing sensation with the intercostal EV-ICD Lead connected to a commercially-available ICD pulse generator programmed to the maximum voltage output and pulse width settings.

Methods
In the STEP ICD Study (n=20), pacing sensation was evaluated at the pre-discharge visit while pacing at the maximum programmable voltage output (7.5 or 8.0 V, depending on manufacturer) and pulse width (1.5 or 2.0 ms). Sensation was reported by the patient as one of four choices: No Sensation, Sensation Only, Tolerable Pain or Intolerable Pain.

Results
Pacing sensation was assessed in 18 of 20 patients. One (1) patient did not undergo a pacing evaluation due to atrial fibrillation with rapid ventricular response. Responses were as follows: No Sensation in 4 (22%) patients, Sensation Only in 10 (56%) patients, Tolerable Pain in 3 (17%) and Intolerable Pain in 1 (6%). In no patient was the pain so severe that pacing capture threshold testing could not be completed. Of note, the single report of intolerable pain was only reported in the sitting posture. When tested supine, the patient reported sensation only.

Conclusion(s)
The design of the investigational intercostal EV-ICD Lead, with button-shaped electrodes backed by an insulative paddle, produced low levels of patient sensation at maximum output and pulse width. These sensation levels represent an improvement over designs that employ ring electrodes and indicate that antitachycardia pacing will be well tolerated with the novel EV-ICD Lead. These results corroborate the predictions about patient discomfort from in silico models.